Versuchen GOLD - Frei

China stands tall in API production and exports

Chronicle Pharmabiz

|

October 30, 2025

THE Active Pharmaceutical Ingredient (API) is the most important part of any drug. The API, as the name would suggest, is the chemical part of any capsule or tablet that works on the disease condition or symptom. This means that the API is the backbone of the pharmaceutical industry, booming in its own right, as it provides the ingredients for all kinds of medication. As the world's largest API production and exporting country, China can produce thousands of species of chemical raw materials.

- By Dr Biplab Debnath & Sumel Ashique

China currently commands an impressive 20 per cent share of global API production by volume, with approximately 40 per cent of APIs exported worldwide originating from Chinese manufacturing facilities.

The global API is already a billion-dollar industry and the overall market is estimated to be worth around $246 billion by 2025. The API manufacturers' productions are influenced by the human cost, materials prices, exchange rate fluctuations and other factors.

The API market in China is projected to experience significant growth from 2025 to 2030. In 2025, the market size is estimated at US$15.97 billion, and it is expected to reach US$23.32 billion by 2030, reflecting a Compound Annual Growth Rate (CAGR) of 7.86 per cent. The major driving factors of global API market are as follows:

■ Growth in healthcare expenditure

■ Advancements in the technology of API manufacturing

■ Rapidly increasing aging population

■ Increasing importance of generics

■ Increase in abbreviated new drug applications (ANDA)

■ Growth in incidence of chronic diseases

Chemical API segment to dominate market

Chemical APIs are produced through conventional routes of synthesis. They are extensively used in many therapeutic segments such as cardiovascular, central nervous system disorder, oncology, gastrointestinal and so on. The wide usage in these applications ensures the stable growth of the chemical API market.

Chemical APIs have historically dominated the global API market, and this situation is reflected in the Chinese market. China is the world's second-largest producer and exporter of chemical APIs, with competitive advantage mainly in antibiotics, vitamins, antipyretics and analgesics.

WEITERE GESCHICHTEN VON Chronicle Pharmabiz

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size